{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:23:37Z","timestamp":1778725417648,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970158"],"award-info":[{"award-number":["81970158"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170205"],"award-info":[{"award-number":["82170205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","award":["2018YFA0107804"],"award-info":[{"award-number":["2018YFA0107804"]}],"id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008235","name":"School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.02.020","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T11:42:35Z","timestamp":1645875755000},"page":"331.e1-331.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"given":"Yibo","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huarui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7051-219X","authenticated-orcid":false,"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.02.020_bib0001","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.bbmt.2013.03.018","article-title":"Clinical guide to ABO-incompatible allogeneic stem cell transplantation","volume":"19","author":"Booth","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0002","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.12933","article-title":"Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program","volume":"93","author":"Kimura","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.02.020_bib0003","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V96.3.1150","article-title":"Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect","volume":"96","author":"Mielcarek","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.020_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000441507","article-title":"ABO-mismatched allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Worel","year":"2016","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.jtct.2022.02.020_bib0005","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/bmt.2011.135","article-title":"Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation","volume":"46","author":"Rowley","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0006","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2017.199","article-title":"Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants","volume":"32","author":"Wang","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.02.020_bib0007","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/ctr.12840","article-title":"ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation","volume":"30","author":"Grube","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0008","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3324\/haematol.2016.160804","article-title":"Impact of ABO incompatibility on patient's outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT","volume":"102","author":"Canaani","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.02.020_bib0009","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ajh.24771","article-title":"ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: a report from the acute leukemia working party of the EBMT","volume":"92","author":"Canaani","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.bmt.1704816","article-title":"Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation","volume":"35","author":"Kim","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0011","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2017.02.009","article-title":"Donor-to-recipient ABO mismatch does not impact outcomes of allogeneic hematopoietic cell transplantation regardless of graft source","volume":"23","author":"Damodar","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0012","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbmt.2013.11.011","article-title":"Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Watz","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0013","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.08073.x","article-title":"The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation","volume":"149","author":"Wang","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0014","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.bbmt.2010.03.021","article-title":"Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source","volume":"16","author":"Blin","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/imj.12894","article-title":"Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation","volume":"45","author":"Le Viellez","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtct.2022.02.020_bib0016","first-page":"139","article-title":"ABO incompatibility and hematopoietic stem cell transplantation outcomes","volume":"11","author":"Vaezi","year":"2017","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.jtct.2022.02.020_bib0017","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/bmt.2016.264","article-title":"ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation","volume":"52","author":"Solves","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0018","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.bbmt.2016.07.019","article-title":"Impact of graft\u2013recipient ABO compatibility on outcomes after umbilical cord blood transplant for nonmalignant disease","volume":"22","author":"Kudek","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0019","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.020_bib0020","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41409-020-01088-7","article-title":"Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis","volume":"56","author":"Yang","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0023","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1111\/trf.15531","article-title":"RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation","volume":"59","author":"Yuan","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2022.02.020_bib0024","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bbmt.2020.03.009","article-title":"Risk factors, clinical outcomes, and cost-of-care related to graft failure in pediatric allogeneic hematopoietic cell transplant recipients","volume":"26","author":"Wobma","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/bmt.2015.351","article-title":"Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI","volume":"51","author":"Cluzeau","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0026","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2016-03-702803","article-title":"Atorvastatin enhances endothelial cell function in posttransplant poor graft function","volume":"128","author":"Shi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.020_bib0027","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","article-title":"Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Zhao","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0028","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00277-015-2440-x","article-title":"The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation","volume":"94","author":"Sun","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0029","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.020_bib0030","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2022.02.020_bib0031","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0032","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtct.2022.02.020_bib0033","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","article-title":"Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation","volume":"4","author":"Al Malki","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.02.020_bib0034","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.CCR-20-2809","article-title":"Comparison of haploidentical bone marrow versus matched unrelated donor peripheral blood stem cell transplantation with posttransplant cyclophosphamide in patients with acute leukemia","volume":"27","author":"Nagler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.02.020_bib0035","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1158\/1078-0432.CCR-15-2335","article-title":"Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study","volume":"22","author":"Wang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.02.020_bib0036","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","article-title":"Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning","volume":"20","author":"Raj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0037","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-020-03934-6","article-title":"Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia\/lymphoma patients in non-complete remission","volume":"99","author":"Hirosawa","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0038","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41409-019-0500-x","article-title":"Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients","volume":"54","author":"Granata","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0039","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/bloodadvances.2020001958","article-title":"Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant","volume":"4","author":"Solomon","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.02.020_bib0040","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00277-020-04326-6","article-title":"Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"100","author":"Yuan","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0041","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2014.12.036","article-title":"ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"21","author":"Logan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0042","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0043","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China\u2013recommendations from the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0044","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.02.020_bib0045","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41409-020-0779-7","article-title":"Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia","volume":"55","author":"Ma","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0046","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/11315940-000000000-00000","article-title":"Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology","volume":"70","author":"Gaber","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2022.02.020_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.08.020","article-title":"Comparison of 2 different rabbit anti-thymocyte globulin (r-ATG) preparations: thymocyte r-ATG versus T lymphoblast cell line r-ATG in allogeneic hematopoietic stem cell transplantation for acquired severe aplastic anemia: propensity score-matched analysis","volume":"27","author":"Liu","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.02.020_bib0048","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/s41409-020-0939-9","article-title":"Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series","volume":"55","author":"Gomez-Arteaga","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0049","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/bmt.2016.98","article-title":"Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis","volume":"51","author":"Alchalby","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.020_bib0050","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2019.02.020","article-title":"Donor specific anti-HLA antibodies in haploidentical stem cell transplantation with post transplant cyclophosphamide: risk of graft failure, poor graft function and impact on outcomes","volume":"25","author":"Bramanti","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:36Z","timestamp":1763002956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722000999"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.020","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}